Integra LifeSciences (NASDAQ:IART) Given New $25.00 Price Target at Truist Financial

Integra LifeSciences (NASDAQ:IART) had its price objective lowered by Truist Financial from $37.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports. The firm currently has a hold rating on the life sciences company’s stock.

A number of other research firms have also recently weighed in on IART. Bank of America cut their price target on Integra LifeSciences from $42.00 to $26.00 and set an underperform rating on the stock in a report on Tuesday. JMP Securities cut their target price on Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating on the stock in a research note on Thursday, February 29th. Wells Fargo & Company cut Integra LifeSciences from an overweight rating to an equal weight rating and decreased their price target for the stock from $45.00 to $25.00 in a research note on Tuesday. StockNews.com cut shares of Integra LifeSciences from a buy rating to a hold rating in a research note on Tuesday, April 30th. Finally, Oppenheimer lowered shares of Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences has a consensus rating of Hold and a consensus price target of $36.80.

Integra LifeSciences Price Performance

Shares of IART opened at $25.08 on Tuesday. Integra LifeSciences has a 12 month low of $22.36 and a 12 month high of $51.12. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The stock has a fifty day moving average price of $32.95 and a 200 day moving average price of $38.24. The company has a market cap of $1.97 billion, a P/E ratio of 30.22, a PEG ratio of 0.87 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. The business had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.74 earnings per share. On average, research analysts forecast that Integra LifeSciences will post 3.19 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System increased its holdings in shares of Integra LifeSciences by 1.3% in the third quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock valued at $802,000 after buying an additional 279 shares in the last quarter. Cardinal Capital Management raised its position in shares of Integra LifeSciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock worth $962,000 after purchasing an additional 347 shares during the period. Hexagon Capital Partners LLC raised its position in shares of Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 370 shares during the period. Inspire Investing LLC boosted its position in shares of Integra LifeSciences by 5.1% in the 3rd quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after purchasing an additional 392 shares during the period. Finally, State of Michigan Retirement System increased its stake in Integra LifeSciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after purchasing an additional 400 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.